Bipolar disorder, previously known as manic depression, is a mental disorder characterized by periods of depression and periods of abnormally elevated mood that each last from days to weeks. If the elevated mood is severe or associated with psychosis, it is called mania; if it is less severe, it is called hypomania. During mania, an individual behaves or feels abnormally energetic, happy or irritable, and they often make impulsive decisions with little regard for the consequences. There is usually also a reduced need for sleep during manic phases. During periods of depression, the individual may experience crying and have a negative outlook on life and poor eye contact with others. The risk of suicide is high; over a period of 20 years, 6% of those with bipolar disorder died by suicide, while 30–40% engaged in self-harm. Other mental health issues, such as anxiety disorders and substance use disorders, are commonly associated with bipolar disorder.
John Frederick Joseph Cade AO was an Australian psychiatrist who in 1948 discovered the effects of lithium carbonate as a mood stabilizer in the treatment of bipolar disorder, then known as manic depression. At a time when the standard treatments for psychosis were electroconvulsive therapy and lobotomy, lithium had the distinction of being the first effective medication available to treat a mental illness.
A mood disorder, also known as an affective disorder, is any of a group of conditions of mental and behavioral disorder where a disturbance in the person's mood is the main underlying feature. The classification is in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD).
A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental illnesses. These medications are typically made of synthetic chemical compounds and are usually prescribed in psychiatric settings, potentially involuntarily during commitment. Since the mid-20th century, such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization, thereby lowering the cost of mental health care. The recidivism or rehospitalization of the mentally ill is at a high rate in many countries, and the reasons for the relapses are under research.
Schizoaffective disorder is a mental disorder characterized by abnormal thought processes and an unstable mood. This diagnosis requires symptoms of both schizophrenia and a mood disorder: either bipolar disorder or depression. The main criterion is the presence of psychotic symptoms for at least two weeks without any mood symptoms. Schizoaffective disorder can often be misdiagnosed when the correct diagnosis may be psychotic depression, bipolar I disorder, schizophreniform disorder, or schizophrenia. This is a problem as treatment and prognosis differ greatly for most of these diagnoses.
Depression is a mental state of low mood and aversion to activity. It affects more than 280 million people of all ages. Depression affects a person's thoughts, behavior, feelings, and sense of well-being. Depressed people often experience loss of motivation or interest in, or reduced pleasure or joy from, experiences that would normally bring them pleasure or joy. Depressed mood is a symptom of some mood disorders such as major depressive disorder and dysthymia; it is a normal temporary reaction to life events, such as the loss of a loved one; and it is also a symptom of some physical diseases and a side effect of some drugs and medical treatments. It may feature sadness, difficulty in thinking and concentration and a significant increase or decrease in appetite and time spent sleeping. People experiencing depression may have feelings of dejection or hopelessness and may experience suicidal thoughts. It can either be short term or long term.
Gordon Barraclough Parker AO is an Australian psychiatrist who is scientia professor of psychiatry at the University of New South Wales (UNSW).
The emphasis of the treatment of bipolar disorder is on effective management of the long-term course of the illness, which can involve treatment of emergent symptoms. Treatment methods include pharmacological and psychological techniques.
Cyclical variations in moods and energy levels have been recorded at least as far back as several thousand years. The words "melancholia" and "mania" have their etymologies in Ancient Greek. The word melancholia is derived from melas/μελας, meaning "black", and chole/χολη, meaning "bile" or "gall", indicative of the term's origins in pre-Hippocratic humoral theories. A man known as Aretaeus of Cappadocia has the first records of analyzing the symptoms of depression and mania in the 1st century of Greece. There is documentation that explains how bath salts were used to calm those with manic symptoms and also help those who are dealing with depression. Even today, lithium is used as a treatment to bipolar disorder which is significant because lithium could have been an ingredient in the Greek bath salt. Centuries passed and very little was studied or discovered. It wasn't until the mid-19th century that a French psychiatrist by the name of Jean-Pierre Falret wrote an article describing "circular insanity" and this is believed to be the first recorded diagnosis of bipolar disorder. Years later, in the early 1900s, Emil Kraepelin, a German psychiatrist, analyzed the influence of biology on mental disorders, including bipolar disorder. His studies are still used as the basis of classification of mental disorders today.
Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.
Peter C. Whybrow is an English psychiatrist and award-winning author whose primary research focus has been on understanding the metabolic role of thyroid hormones in the adult brain and how to apply this knowledge to the treatment of mood disorder, especially bipolar disorder. He is Judson Braun Distinguished Professor in the Department of Psychiatry and Biobehavioral Sciences of the David Geffen School of Medicine at UCLA.
The Royal Australian and New Zealand College of Psychiatrists (RANZCP) is the principal organisation representing the medical specialty of psychiatry in Australia and New Zealand and has responsibility for training, examining and awarding the qualification of Fellowship of the College (FRANZCP) to medical practitioners. The college was established on 9 October 1946, and received Royal patronage in 1977.
The following outline is provided as an overview of and topical guide to psychiatry:
Ronald Robert Fieve was an American psychiatrist known for his work on the use of lithium in treatment of mood disorders. He has authored four popular science books, "Moodswing", "Bipolar II", "Prozac" and "Bipolar Breakthrough".
Louise Newman is an Australian developmental psychiatrist and clinical researcher currently based at Monash University, in Melbourne, Australia. She is an advocate for the mental health of asylum seekers.
Augustus John Rush is an internationally renowned psychiatrist. He is a professor emeritus in Duke-NUS Medical School at the National University of Singapore (NUS), and adjunct professor of psychiatry and behavioral sciences at Duke University School of Medicine. He has authored and edited more than 10 books, and over 600 scientific journal articles that are largely focused on the diagnosis and treatment of depressive and bipolar disorders.
Lori Altshuler was a professor at the University of California, Los Angeles (UCLA) Department of Psychiatry and Biobehavioral Sciences and held the Julia S. Gouw Endowed Chair for Mood Disorders. Altshuler was the Director of the UCLA Mood Disorders Research Program and the UCLA Women's Life Center, each being part of the Neuropsychiatric Hospital at UCLA.
Ellen Frank is a psychologist and Distinguished Professor Emeritus of Psychiatry and Distinguished Professor of Psychology at the University of Pittsburgh. She is known in the field of Psychotherapy as one of the developers of Interpersonal and Social Rhythm Therapy, which aims to treat bipolar disorder by correcting disruptions in the circadian rhythm while promoting increased regularity of daily social routines. Frank is the co-founder and Chief Scientific Officer of HealthRhythms, a company that uses mobile technology to monitor the health and mental health of clients, facilitate the detection of changes in their status, and better manage mental health conditions.
Mauricio Tohen is a Mexican American research psychiatrist, Distinguished Professor, and Chairman of the Department of Psychiatry & Behavioral Sciences at the University of New Mexico. Tohen's research has focused on the epidemiology, outcome, and treatment of bipolar and psychotic disorders, and is especially known for innovating the design of clinical trials and the criteria to determine outcome in such diseases. Tohen has edited several books on his specialties. His social awareness has been noted in the promotion of programs to improve mental health care in areas such as substance abuse, bipolar disorder and schizophrenia.
Susan Lynn McElroy is Chief Research Officer at Lindner Center of HOPE.
